Inhibition of HIV replication in vitro by fusidic acid.
A 58-year-old man with AIDS improved clinically after the introduction of fusidic acid, 500 mg three times a day orally, to his therapeutic regimen. Fusidic acid may have had a direct effect against HIV. Fusidic acid has anti-HIV activity in vitro at levels readily attainable in vivo. The drug does not appear to be a reverse transcriptase inhibitor and its mode of action against HIV is unknown. Fusidic acid can be given orally and has few side-effects. These results justify fuller evaluation of fusidic acid as therapy against AIDS and HIV infection.
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy; D003588:Cytopathogenic Effect, Viral / Q000187:drug effects; D004359:Drug Therapy, Combination; D005672:Fusidic Acid / Q000494:pharmacology* / Q000627:therapeutic use; D006678:HIV / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D018894:Reverse Transcriptase Inhibitors; D014779:Virus Replication / Q000187:drug effects*
D018894:Reverse Transcriptase Inhibitors; D005672:Fusidic Acid